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DObjective: Human recombinant erythropoietin has been used to obtain a rapid increase in red blood cells before
surgery. Previously, the shortest preparatory interval has been 4 days, but at the European Hospital only 2.4 days
on average separate hospitalization and surgery. We therefore proposed a randomized blind trial to test the effi-
cacy of high-dose erythropoietin for very short-term administration.
Methods: All patients presenting with a diagnosis of isolated coronary vessel disease were randomized to either
erythropoietin therapy or a control group. Patients with a creatinine level greater than 2 mg/dL or hemoglobin
level greater than 14.5 g/dL were excluded. Hemoglobin values were collected preoperatively and on postoper-
ative days 1 and 4. Blood loss and blood transfusion rate were recorded at the time of discharge.
Results: We enrolled 320 consecutive patients in the study. No significant difference was found in preoperative
parameters, postoperative blood loss, or mean preoperative hemoglobin levels. On postoperative day 4, mean he-
moglobin was 15.5% higher in the erythropoietin group (10.70  0.72 g/dL vs 9.26  0.71 g/dL; P<.05). This
group required 0.33 units of blood per patient, whereas the controls required 0.76 units per patient (risk ratio 0.43,
P ¼ .008).
Conclusion: A significant reduction in transfusion rate and a significant increase in hemoglobin values were ob-
served in the erythropoietin group. No adverse events related to erythropoietin administration were recorded. A
very short preoperative erythropoietin administration seems to be a safe and easy method to reduce the need for
blood transfusions. (J Thorac Cardiovasc Surg 2010;139:621-7)Earn CME credits at
http://cme.ctsnetjournals.org
The use of blood conservation techniques is important in
cardiac surgery, because postoperative bleeding is common
and allogenic blood transfusion carries the risk of transfu-
sion reactions and infection. Specifically, in isolated coro-
nary artery bypass grafting (CABG) the transfusion of
allogenic blood increases the risk for postoperative atrial fi-
brillation, worsens health-related quality of life, and reduces
long-term survival.1-3 According to recent reports, more
than one third of patients undergoing elective CABG still re-
quire allogenic blood, and approximately 20% of transfu-
sions are associated with cardiac surgery. Erythropoietin
with and without preoperative autologous blood donation
is one way to minimize allogenic transfusion.4 Erythropoie-
tin is a 165 amino acid glycoprotein hormone with a molec-
ular weight of approximately 30 kDa. It is synthesizede Cardiac Surgery Department, European Hospital, Rome, Italy.
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The Journal of Thoracic and Caprimarily by the kidneys in adults and by the kidneys and
liver in the fetus. The ratio between kidney and liver eryth-
ropoietin in adults is 9:1. Its primary role involves the
prevention of programmed cell death (apoptosis) of erythro-
cyte precursors. Erythropoietin induces erythropoiesis by
promoting the proliferation and differentiation of erythroid
progenitor cells, the main target cell being the colony-form-
ing unit erythroid.
In addition to erythropoietin’s well-known effect on red
blood cell mass in response to changes in tissue oxygena-
tion, many investigations have shown that it also exerts a pro-
tective role against tissue ischemia. It is believed that this is
achieved both directly by activating multiple biochemical
mechanisms that provide anti-apoptotic, anti-oxidative,
and anti-inflammatory responses to hypoxia/anoxia, and in-
directly via its angiogenic potential by inducing a systematic
oxygen supply to the ischemic tissue.5
Recombinant human erythropoietin (HRE) was developed
in the mid-1980s and is commercially available in several
forms. Erythropoietin combined with oral iron therapy is
used to treat anemia (hemoglobin [Hb]<13 g/dL) in renal
failure, associated with chemotherapy or human immunode-
ficiency virus, and when given preoperatively, to reduce
transfusion in a wide range of operations. Abundant evi-
dence, including 4 meta-analyses,6-9 exists to justify the pre-
operative administration of HRE to reduce preoperative
anemia, especially in patients undergoing autologous blood
donation10-13 and in children.14,15 Erythropoietin seems tordiovascular Surgery c Volume 139, Number 3 621
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
CABG ¼ coronary artery bypass grafting
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Dbe safe and effective for the improvement of preoperative
anemia. Preoperative interventions using HRE seem justified
for elective patients with diminished blood volume because
of the high risk of excessive blood transfusion in this subset.
Still fewer objective data are available regarding the use of
HRE to treat peri- and postoperative anemia. Because the on-
set of drug action is 4 to 6 days, it has been considered nec-
essary to administer HRE a few days before the operation.
There are some conditions in which the production of endog-
enous HRE is limited: beta-blocker therapy, cytokines stim-
ulated by the inflammatory response associated with
cardiopulmonary bypass, and perioperative renal ischemia.
Likewise, careful perioperative management may improve
tissue oxygen delivery and suppress endogenous HRE pro-
duction despite postoperative anemia. All of these factors
support the addition of preoperative (ie, a few days before
surgery) administration of HRE to treat reduced red blood
cell volume in selected patients.16,17 So far, the shortest pre-
paratory administration interval has been up to 4 days preop-
eratively.
At the European Hospital, an average of only 2.4 days
separate hospitalization and surgery, and inpatient optimiza-
tion procedures are pushing this limit even further. This sit-
uation is common in many high-volume centers, making any
protocol requiring the patient to wait more than 3 days be-
fore operation unattractive and practically useless. We there-
fore proposed a randomized blind trial to test the efficacy of
high-dose HRE in very short-term administration, a protocol
that does not change the usual interval between admission
and surgery. Should the advantages of HRE administration
be present even with such a short interval, its use could be
advisable as part of the routine strategy to minimize the
use of allogenic blood transfusions.MATERIALS AND METHODS
All patients presenting with a diagnosis of isolated coronary vessel dis-
ease at the European Hospital were considered for the study. Exclusion cri-
teria were the presence of high Hb values (>14.5 g/dL, or hematocrit>
44%), confirmed renal impairment (creatinine> 2 mg/dL), or the need
for on-pump revascularization. The decision to exclude the latter was
made to avoid the confounding factor of extracorporeal circulation, which
implies an increase in hemodilution and blood loss.
All patients’ risk factors for ischemic heart disease (family history, the
presence of diabetes, hypercholesterolemia, smoking, obesity, hyperten-
sion); factors included in the EuroSCORE analysis (age, gender, chronic
pulmonary obstructive disease, the presence of extracardiac arteriopathy,
neurologic dysfunction, previous cardiac surgery, serum creatinine, active622 The Journal of Thoracic and Cardiovascular Surgendocarditis, critical preoperative state, unstable angina, left ventricle dys-
function, recent myocardial infarct, pulmonary hypertension, emergency
conditions, postinfarct septal rupture); and biometric parameters (height,
weight, and body surface area) were collected and stored in the database be-
fore the results of randomization were known. A custom simple application
running in Windows XP (Microsoft Corp, Redmond, WA) was used to ob-
tain randomization tables, and the next value of the table was kept secret un-
til a suitable patient was enrolled. This study adheres to the CONSORT
principles, and patients followed the CONSORT 2005 FlowChart.
Informed consent was then obtained, and all aspects of the operation,
drug administration, and any other relevant matter were explained to the pa-
tient by one of the investigators. The study followed the Helsinki Declara-
tion requirements for randomized case-control trials and was approved by
the institutional review board of the European Hospital.
The patients randomized to the HRE group received 14,000 IU via sub-
cutaneous administration 2 days before the operation, 14,000 IU on the next
day, 8000 IU on the morning of the operation, 8000 IU 1 day after operation,
and 8000 IU on postoperative day 2. The control group received no treat-
ment. Despite known interactions of HRE with other medications (eg,
beta-blockers), all standard therapies were maintained until the day of oper-
ation. The patients, nurses, and ward physician knew whether HRE was be-
ing administered or not, but the investigators did not, nor did they have any
chance to influence the clinical decision as to whether or not to give allo-
genic blood, thus fulfilling the conditions for a single-blinded study.
The primary end point was the need for allogenic transfusion. The sec-
ondary end point was the Hb value on postoperative day 4. Ancillary objec-
tives were the Hb trend from baseline to day 4 with and without HRE
administration, and the cost-effectiveness of HRE versus the reduced
need for transfusion.
Transfusion need was triggered by Hb levels less than 8.0 g/dL, and the
same criteria were applied to both groups. Hb values were automatically col-
lected by the central laboratory computer on the day of admission, on the
day of surgery, and on postoperative day 4. The number of units transfused,
the amount of blood loss, any kind of adverse reaction, and the patient’s out-
come were collected directly from the clinical records 2 weeks after dis-
charge. All patients underwent outpatient follow-up approximately 45
days after surgery, at which time all adverse events were investigated.
All data were processed by SPSS version 16 (SPSS Inc, Chicago, Ill), in-
cluding sample sizing, analysis of variance (ANOVA), and risk analysis. A
preliminary power estimation analysis suggested that 160 patients per sam-
ple were needed to obtain a 90% power goal, considering an alpha error
level of 5% and expecting the incidence of transfusion to decrease from
the previously observed 30% to 15%.
The first step of analysis was to ascertain whether the randomization pro-
cess had been effective in controlling as many known confounding factors
as possible. ANOVA of the dependent variables ‘‘HRE or control’’ was per-
formed (ANOVA and univariate ANOVA as needed, 95% confidence inter-
val, P .05; full list of parameters and P values are shown in Table 1) on all
preoperative data, namely, general cardiovascular risk parameters, Euro-
SCORE risk parameters, biometric parameters, and blood loss.
The second step was to verify whether the 2 groups really differed in
terms of Hb value on day 4, transfusion rate, relative risk of undergoing al-
logenic blood transfusion, duration of hospital stay, and adverse events. Ev-
ery comparison was tested with several statistical techniques (Student t test,
univariate regression, Yates’ continuity-corrected chi-square test as needed)
as appropriate.
The general statistical aspect of the study was kept as simple as possible in
the belief that even if sophisticated statistical techniques exist to control the
influence of confounding factors, accurate planning remains the best tool.RESULTS
Recruitment took place between October 1, 2007, and
September 31, 2008, and 400 patients were assessed forery c March 2010
TABLE 1. Baseline characteristics of the study population and
analysis of variance P value
HRE Control P alue
Family history 40.6% 38.2% .342
Obesity 19.8% 19.6% .98
Diabetes 44.4% 40.5% .342
Hypercholesterolemia 59.3% 67.7% .851
Smoking habit 52.1% 53.3% .349
Hypertension 77.8% 78.5% .260
EuroSCORE 7.94  8.07 6.82  10.39 .372
Age 66.9  9.11 66.4  10.8 .735
Gender Male, 84% Male, 83% .169
Chronic pulmonary
obstructie disease
32.1% 16.5% .079
Presence of extracardiac
arteriopathy
23.5% 15.8% .454
Neurologic dysfunction
disease
2.9% 1.9% .913
Preious cardiac surgery 1.8% 0.6% .332
Serum creatinine 1.08  0.30 1.14  0.32 .206
Seere renal impairment 0% 0% NA
Presence of actie endocarditis 0% 0% NA
Critical preoperatie state 0% 0.6% NA
Unstable angina 27.9% 26.6% .177
Ejection fraction 54.11  7.87 53.03  8.82 .344
Recent myocardial infarct 34.4% 30.4% .344
Pulmonary hypertension 0% 0.6% .487
Postinfarct septal rupture 0% 0% NA
Height 169  7.8 168  8.5 .426
Weight 80.94  13 76.83  11.41 .344
Body surface area (m2) 1.74  0.88 1.67  0.77 .227
Baseline Hb (g/dL) 13.18  1.21 13.44  1.20 .183
Blood loss (mL) 605  373 554  326 .479
Hb, Hemoglobin; HRE, human erythropoietin; NA, not applicable.
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Deligibility; 80 patients were excluded from the study
(60 patients did not meet the inclusion criteria, 11 patients
refused to participate, and 9 patients were excluded for other
reasons). Of the remaining 320 patients, 158 were allocated
to HRE administration and all received the intended treat-
ment; 162 were allocated to the control group. Two patients
in the HRE group and 1 patient in the control group were
converted to on-pump revascularization. These patients
were considered as intention-to-treat and were therefore
included in the analysis.
ANOVA confirmed the efficacy of the randomization
process, because all variables analyzed proved to have no
statistically significant difference between the 2 groups
(Table 1). The baseline demographic and clinical character-
istics of each group are also summarized in Table 1. Both
groups used the cell-saver system during the operation and
received standardized doses of a fibrinolytic agent (tranexa-
mic acid). There was no statistical difference between the
groups in terms of assignment to a specific investigator
(P ¼ .323). For the HRE and control groups, the time in
the operating suite was 168 and 146 minutes, respectively
(P ¼ .342); the number of grafts performed was 3.11 and
3.16, respectively (P ¼ .677); the percentage of take-backs
for bleeding was 1.30% and 1.25%, respectively (P ¼
.32); and the clotting factors transfused were 0.08 and
0.09 units of plasma per patient, respectively (P ¼ .612),
and 0.04 and 0.03 units of platelets per patient, respectively
(P ¼ .132). Baseline Hb showed no significant difference
between the groups (P> .3), nor did blood loss (587 vs
616 mL, P ¼ .43).
On postoperative day 4, Hb was 10.70  0.72 g/dL in the
HRE group and 9.26  0.71 g/dL in the control group (P ¼
.03, 95% confidence interval). The HRE group required
0.32 units of blood per patient, whereas the control group re-
quired 0.76 units per patient, and this difference proved to be
highly significant (P ¼ .008). In greater detail, 15.82% of
patients (25/158) in the HRE group required transfusion,
8.86% (14) requiring 1 unit, 4.43% (7) requiring 2 units,
and 2.53% (4) requiring 3 or more units. In the control
group, 37.2% of patients (60/162) required transfusion,
11.72% (19) requiring 1 unit, 19.75% (32) requiring 2 units,
and 5.55% (9) requiring 3 or more units. The risk ratio of
being exposed to allogenic blood was 0.425 (P ¼ .007,
95% confidence interval) for the HRE group versus the con-
trol group (Figure 1).
Table 2 shows the adverse events analysis, with differ-
ences in terms of 45-day mortality, in-hospital complica-
tions, and mid-term morbidity. Briefly, there was no
difference in 45-day mortality (3 patients in each group,
1.92% vs 1.86% P¼ .672). In regard to in-hospital compli-
cations, patients in the control group had a lower incidence
of cardiac tamponade and increased plasma liver enzymes,
a higher incidence of positive blood, sputum, and urine cul-
tures, and higher peak troponin values. On mid-term follow-The Journal of Thoracic and Caup (45 days), the control group showed a higher incidence of
neurologic events and deep vein thrombosis. All differences
presented with a low level of significance. The 2 populations
did not differ for the other parameters considered.
With V243 as the protocol expense for the HRE group,
the cost of 1 unit of blood beingV270, the saving of approx-
imately half a unit of blood per patient was not cost-effec-
tive. Nevertheless, a net reduction of 1 unit of blood for
every 2 patients is an acceptable gain in terms of overall
risk reduction. Moreover, by focusing on a higher-risk pop-
ulation, starting with baseline Hb less than 10.5 g/dL, the ad-
vantage in terms of spared blood units is higher (0.28 units/
patient vs 0.99 units/patient, P ¼ .012).
There was a slight difference in the duration of hospital
stay, with an advantage for the HRE group of 5.32 days ver-
sus 5.89 days, but the difference was not significant (P ¼
.08). However, if confirmed, the increased length of stay
of 0.57 days per patient would increase the cost of the con-
trol group by V456 per patient, thus making the protocol
eventually convenient.rdiovascular Surgery c Volume 139, Number 3 623
FIGURE 1. Risk of exposure to allogenic blood transfusion (P ¼ .007).
HRE, Human erythropoietin.
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DDISCUSSION
The focus of this randomized blind study was to assess
whether a high dose of HRE administered shortly before sur-
gery is advantageous, safe, and cost-effective in reducing the
risk of exposure to allogenic blood transfusion.
The importance of blood conservation techniques is well
known in cardiac surgery, because postoperative bleeding is
common and allogenic transfusion carries the risks of both
transfusion reactions and infection transmission. Despite
all efforts, approximately one third of patients undergoing
elective CABG still require allogenic blood.
The guidelines for blood conservation have emphasized
the need for a multifactorial approach, and erythropoietin ad-
ministration with and without preoperative autologous blood
donation is one of the recommended modalities to minimize
allogenic blood transfusion.
Although recombinant human HRE was developed in the
mid-1980s, and abundant evidence, including 4 meta-analy-
ses,6-9 exists to justify its preoperative administration to re-
duce perioperative anemia, there is still no consensus
regarding its use. One main practical concern is that obtain-
ing the full effect of HRE takes more time than is usually
available in a high-volume, efficiency-oriented center. A
typical preoperative HRE regimen is costly, and there is
uncertainty about its cost-effectiveness for patients undergo-
ing autologous blood donation before cardiac procedures.
Evidence supporting the preoperative use of HRE in anemic
patients (Hb<13 g/dL) without autologous pre-donation is
less compelling, but still supportive. Most of the literature
supporting the use of HRE to reduce preoperative anemia
is anecdotal and relates to successful case reports in a handful
of patients, especially Jehovah’s Witnesses. Because preop-
erative anemia increases mortality and morbidity in cardiac
procedures, HRE can be expected to reduce it by augment-
ing red cell mass in anemic patients treated with iron, if
given more than 1 week before operation. This recommen-
dation is based on limited evidence and logical consensus.
In our search for a strategy suitable for routine use, we
thought that a boost to red cell growth could only be conve-
nient if present shortly after HRE administration, thereby624 The Journal of Thoracic and Cardiovascular Surgpreventing the patient waiting longer than strictly necessary
for the operation. To our knowledge, no other published stud-
ies had ever tested the efficacy of this drug in such a context.
Many studies based on decision analysis models con-
cluded that the use of HRE reduces the risk of exposure to
allogenic blood transfusion.18,19 Our experience shows
that HRE administration has a significantly (P ¼ .007) pro-
tective effect, roughly halving this risk, and significantly (P
¼ .03) increases the Hb value on day 4 after surgery by
15.55%.
The safety of HRE is an important area to address. D’Am-
bra and colleagues20 reported an increased frequency of
mortality during the study or within 2 months of discontin-
uation of the double-blind therapy, but their results were
not significant (P ¼ .06). However, this was the only study
in which HRE administration showed an increase in mortal-
ity, albeit not significantly. Hayashi and colleagues21 re-
ported that 2 patients were removed from their trial
because of the adverse events of HRE therapy (fatigue and
dizziness developed in 1 patient, and skin rash and hyperten-
sion developed in 1 patient). Although hypertension is more
likely to be associated with long-term HRE therapy, there
have been reports of hypertension developing during
short-term treatment in individual patients without a history
of hypertension.22 Moreover, D’Ambra and colleagues
found no significant difference in the nonfatal complications
of therapy between the HRE and the placebo groups.
We observed no difference in terms of mortality 45 days
after the operation. The analysis of adverse events occurring
during the hospitalization seems to indicate that HRE admin-
istration is not an increased risk factor. The analysis of ad-
verse events occurring in the first 45 days after operation
showed no difference in terms of myocardial infarction, re-
nal failure, pneumonia, or wound infection. However, the
control group had a slightly higher incidence of neurologic
ischemic events and deep vein thrombosis. No new-onset
hypertension was observed in either group.
Our data show that short-term, high-dose administration
of HRE does not correlate with increased complications
and should therefore be considered safe. One possible expla-
nation for this is the structure of the protocol itself. We know
that increasing blood viscosity is a prothrombotic procedure.
This has always been the major concern regarding HRE use
in patients with vascular disease. However, in this specific
case patients at risk of developing high hematocrit (Hb
>14.5) are excluded from the protocol. Moreover, 48 hours
after initial administration of the drug another event occurs
to dramatically reduce the risk of thrombosis, that is, peri-
and postoperative blood loss. Bleeding occurs just before
the peak effect of HRE, thereby minimizing the risk of ex-
cessive blood viscosity; in fact, no patient had an Hb level
greater than 14.0 g/dL on the day of discharge.
Finally, uncertainty exists about the cost-effectiveness of
HRE for patients undergoing cardiac procedures. A typicalery c March 2010
TABLE 2. Postoperative morbidity analysis
HRE Control P value
ICU stay (d) 1.571 1.567 .89
Perioperative MI (%) 2.02 2.31 .53
Peak troponin level (nmol/L) 0.841667 4.576694 .05
Epileptic syndrome (%) 0.00 0.63 .12
Focal neurologic damage (%) 0.00 0.63 .14
Generalized neurologic damage (%) 0.00 0.63 .16
Total bleeding (mL) 587.1429 616.0484 .43
Bleeding at 6 h (mL) 198.5185 271.2941 .28
Bleeding at 12 h (mL) 299.2593 360.5882 .42
Bleeding at 24 h (mL) 375.6 452.8 .36
Revision for hemostasis (%) 1.30 1.25 .32
Cardiac tamponade (%) 2.00 0.63 .05
Atrial fibrillation (%) 2.5% 2.4% .45
Patients transfused in ICU (%) 22.00 36.25 .001
Acute respiratory distress syndrome (%) 4.00 4.32 .43
Acute pulmonary edema (%) 0.00 0.00 NA
Pneumonia (%) 0.00 0.00 NA
Need for reintubation (%) 0.00 0.63 .22
Increase in liver enzymes (%) 2.00 0.00 .03
Increase in pancreatic enzymes (%) 0.00 0.00 na
Bowel ischemia (%) 0.00 0.00 na
Creatinine level before surgery (mmol/L) 1.1825 1.104889 .34
Maximum creatinine level (mmol/L) 1.189744 1.074715 .23
First 24-h urine output (mL) 1925.897 1891.009 .45
Use of fenoldopam (%) 8.00 5.00 .07
Need for CVVHDF 2.00 0.63 .09
Need for insulin infusion (%) 18.00 15.00 .1
Positive blood culture (%) 0.00 0.63 .02
Positive urine culture (%) 0.00 0.63 .03
Positive sputum culture (%) 0.00 0.63 .02
Positive sternal wound culture (%) 0.00 0.00 NA
Fluid balance on discharge from ICU (mL) 503.6923 447.9344 .32
Central venous pressure (mm Hg) 8.297297 8.237705 .88
Length of stay after operation (d) 5.52 5.89 .065
Neurologic complications at 45 d (%) 0.00 1.88 .02
Long-term wound infection (%) 2.00 1.88 .65
Deep vein thrombosis (%) 0.00 0.63 .03
Acute hypertension onset (%) 0.00 0.00 NA
Renal failure (%) 0.00 0.00 NA
45-d mortality (%) 1.92 1.86 .67
CVVHDF, Continuous veno-venous hemodiafiltration; HRE, human erythropoietin; ICU, intensive care unit; MI, myocardial infarction; NA, not applicable.
Weltert et al Acquired Cardiovascular Disease
A
C
Dpreoperative regimen of HRE is costly, and at least 2 studies
showed that it was not cost-effective.18,19 We carried out an
ancillary analysis considering the cost-effectiveness of the
procedure: Our protocol expense was V243, and 1 unit of
blood requested electively cost V270, which increased to
V390 euros if requested in an emergency. The use of HRE
resulted in a saving of 1 unit of blood for every 2 patients,
and therefore was not cost-effective, even though the patient
had a net gain in terms of risk reduction for immunologic re-
action, infective disease transmission, and atrial fibrillation,
as well as a better health-related quality of life after cardiac
surgery and even long-term survival after CABG.1-3 StrataThe Journal of Thoracic and Caanalysis showed that the protective effect is far greater for
patients with baseline Hb less than 10.5 g/dL; therefore,
10.5 g/dL can be considered a threshold to gain the maxi-
mum clinical benefit and minimize the added cost.
STUDY LIMITATIONS
There are some limitations to this study. First, the choice
to exclude patients receiving on-pump surgery eliminated
the bias related to extracorporeal circulation, but at the
same time excluded from the study those patients with low
red blood cell volume requiring urgent, high-risk surgery us-
ing cardiopulmonary bypass. Although these patients wererdiovascular Surgery c Volume 139, Number 3 625
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Da minority (in our population, planned on-pump revascular-
ization was limited to 56 of 400 patients, 13.5% of the total),
they were the patients who would have benefited more from
the protocol. Second, the lack of long-term follow-up could
miss some late complications that were not evident at 45
days. Third, possible interactions with other drugs (eg,
beta-blockers) were not investigated, and the effect of in-
creased perioperative oxygenation that might reduce the
stimulus for endogenous erythropoietin production, making
exogenous erythropoietin a more desirable option, was not
taken into account. Finally, because of their lack of availabil-
ity in Italy, neither aprotinin nor Amicar was used as part of
the multifactorial blood-sparing strategy.
CONCLUSIONS
High-dose HRE administration, even in the very short
term, leads to a significant reduction in transfusion rate
and a significant increase in Hb values, thereby almost halv-
ing the risk of allogenic blood transfusion. No adverse
events related to HRE administration were recorded. A
very short preoperative administration of HRE seems to be
a safe and easy method to reduce the need for allogenic
blood transfusion and may be considered as part of a multi-
factorial strategy toward a further reduction for the need of
transfusion in heart surgery.
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Dr Colleen Koch (Cleveland, Ohio). You present intriguing
data demonstrating reduced red cell transfusion in patients receiv-
ing very short-term use of erythropoietin. I have 3 questions for
you, and they pertain to the timing of administration, adverse
events, and cost.
The first is with regard to timing. One of the biggest hurdles for
the use of erythropoietin in the cardiac surgical setting is the short
time interval between patient evaluation and the eventual operation.
You demonstrated feasibility and effectiveness for reducing red cell
transfusion as well as increasing day 4 hemoglobin. My question
for you is, what were your indications for transfusion in this study?
Meaning, was there a transfusion policy such that patients who
were in your control group and erythropoietin group had a similar
hemoglobin trigger that initiated a red cell transfusion?
Dr Weltert. Yes, of course we have a transfusion policy. We
transfuse when the patient’s hemoglobin decreases to less than 8
g/dL in the absence of symptoms and when blood exsanguination
as estimated by saturation of venous blood decreases to less than
50% even with optimal hemoglobin values, and, of course, this
policy did not differ between the 2 groups.
Dr Koch. Wonderful. Now, my second question pertains to ad-
verse events, and one of the major concerns with the use of eryth-
ropoietin in the cardiac surgical setting is the risk of thrombosis and
thromboembolism. You reported no increase in risk of thrombosis
or thromboembolism for those patients who received erythropoie-
tin. Of note, in the United States the Food and Drug Administration
has not approved erythropoietin for the specific use of decreasing
red cell transfusion in cardiac surgery. So my question is, why do
you think you did not find an increased risk for thrombosis? Is there
some way you manage the patients differently, anticipating that this
might be a risk for complications?
DrWeltert.Good question. It was a surprise to us as well to find
no complication at all. A few minor complications have been
reported, such as rash, dizziness, fatigue, and a low incidence of
thrombosis. So we expected to find some, approximately 1%. As
I said, we had absolutely no adverse event.ery c March 2010
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DOne possible explanation, one possible pitfall of the study is that
we ended the follow-up on day 4. So we can’t ascertain if some-
thing has happened after discharge. I can tell you now confiden-
tially that nothing has happened, because in Italy the patient
usually comes back to you whatever happens, and nobody has
come back.
Dr Koch. My final question pertains to cost. Another concern
for the use of erythropoietin is the cost of administration. You
were unable to demonstrate a cost benefit to the use of erythropoi-
etin in comparison with reduced red cell transfusion. There are data
to suggest that patients who received red cell transfusions have
a longer time on the ventilator postoperatively, an increased infec-
tion rate that needs treatment, and prolonged intensive care unit and
hospital length of stay. Can you speculate on whether or not if
you included the cost of morbid events related to transfusion in
your modeling, there would have been a cost benefit to the use of
erythropoietin?
Dr Weltert. I know from performed second-level analysis that
if we expanded the cost analysis to complications, this protocol
would be convenient, but I had to stick to the simpler approach
declared as the secondary end point. On further analysis,
however, the protocol sort of moved patients 1 unit down. So if
patients received 1 unit of blood, they were placed in a no trans-
fusion category and so on. The protocol failed to demonstrate
efficacy in the subset with more than 3 units of blood. There
was no difference in terms of length of stay in hospital. So I
can’t say there is direct evidence of cost enhancements in this
kind of analysis, but if we put everything together it will probably
become convenient, yes.
Dr Koch. Thank you.
Dr Beat Walpoth (Geneva, Switzerland). At least experimen-
tally there is some literature indicating that high-dose erythropoie-
tin in a peri-ischemic model is brain and heart protective. Did you
look at these issues in your large patient cohort?The Journal of Thoracic and CaDr Weltert. I know these studies. When I planned the study, I
tried to keep it as simple as possible with a clear primary end
point and a simple secondary end point. The studies in literature
usually fail to demonstrate statistically the evidence of associa-
tion. I didn’t want to get into that difficult topic, so I did not col-
lect these data. However, the risks of thrombosis and ischemia
are minimized by the inclusion criteria (patients with high hemat-
ocrit were excluded) and by the fact that every patient loses blood
after the operation exactly on the day of maximal bone marrow
output, thus lowering hematocrit and keeping it indirectly in
a safe range.
Dr R. Duane Davis (Durham, NC). Can you comment on what
you use for your antiplatelet therapy postoperatively, and how did
you assess for myocardial ischemic or infarction events?
DrWeltert. We followed the European guidelines for antiplate-
let medications and diagnosis of ischemic events. More specifi-
cally, we used 100 mg of acetyl salicylic acid since day 1 for the
patient without previous ischemic cardiac events, and we used an
association of aspirin and clopidogrel when myocardial infarction
or ischemia occurred in the 15 days before surgery.
Dr Patricia M. Cruchley (Kitchener, Ontario, Canada). Your
hemoglobin levels were quite high. Have you tried to separate out
your patients in each group to see if the patients who were anemic
received some benefit from the erythropoietin versus the whole
group with their hemoglobin level of 134 g/dL or whatever your
average was?
DrWeltert.Yes, absolutely. The subset of patients with a hemo-
globin less than 9 g/dL had the highest benefit from the protocol.
The protocol does not give a statistical significant advantage on
day 1. We collected the analysis, but I didn’t speak about that
because there was no difference. But it shows a difference on day
4. The difference is inversely proportional to the starting point.
So, yes, the subset who has the most benefit is the one starting
with low hemoglobin.rdiovascular Surgery c Volume 139, Number 3 627
